We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Smith & Nephew (SNN) Now
Read MoreHide Full Article
Smith & Nephew plc (SNN - Free Report) is poised for growth on solid fundamentals across majority of its segments and the integration of Ceterix Orthopaedics.
Over the past six months, the Zacks Rank #1 (Strong Buy) stock has gained 8.9% against the industry's decline of 2.5%. The current level also compares favorably with the S&P 500 index’s 2.8% decline.
What’s Working in Favor of Smith & Nephew?
Strong franchise performance:
Of late, the company is showing strong revenue performance across majority of its key operating franchises. In the last reported quarter, growth within the company’s Reconstruction segment was driven by strong momentum within the knees and hips sub-segments. The knees sub-segment was driven by double-digit growth in JOURNEY II, ANTHEM and the LEGION Revision System. Growth within the hips subsegment came from the company’s increased focus on POLAR3 and REDAPT Revision System. The launch of the dual mobility product with its OXINIUM bearing has been a key development within this sub-segment.
Within the Arthroscopic Enabling Technologies segment, one crucial development has been the launch of the Flow 90 Wand, which expanded the application of the company’s COBLATION technology. The company is also witnessing a sharp increase in NAVIO robot and capital sales within its Surgical Business segment.
The franchise of Sports Medicine and Trauma also reported solid growth in the last quarter. This segment was driven by growth of the company’s joint repair business, especially doubled sales of its REGENETEN rotator cuff repair device. The franchise of Trauma and Extremities reported growth on the company’s EVOS and INTERTAIN product lines. The Advanced Wound Management segment also registered single-digit growth buoyed by strong sales at its Advanced Wound Care and Advanced Wound Devices portfolios.
Strategic acquisitions:
In January, the company acquired Ceterix Orthopaedics, which strengthened its sports medicine portfolio. The market is currently upbeat about Smith & Nephew’s plan to take over Brainlab Orthopaedic Joint Reconstruction Business to augment its newly-launchedmulti-asset digital surgery and robotic ecosystem. The company has also announced an agreement to acquire Osiris Therapeutics which should enable Smith & Nephew to gain a strong foothold in the market of high growth regenerative medicine.
Strong geographic performance:
In the fourth quarter of 2018, the company reported revenue growth of 3% in the United States and 8% across the emerging markets. Revenue growth from China was in double digits. Despite a decline in revenues from its U.K market, the newly-appointed management in Germany is expected to result in solid growth recovery.
Which Way are Estimates Treading?
Further, Smith & Nephew’s estimate revision trend for the current year is favorable. In the past 60 days, two estimates moved up while none shifted down. Consequently, estimates were up from $2 per share to $2.02.
Zacks Rank and Other Key Picks
Currently, Smith & Nephew sports a Zacks Rank #1 (Strong Buy).
Stryker’s long-term earnings growth rate is projected at 10%
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Varian’s long-term earnings growth rate is projected at 8%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Here's Why You Should Invest in Smith & Nephew (SNN) Now
Smith & Nephew plc (SNN - Free Report) is poised for growth on solid fundamentals across majority of its segments and the integration of Ceterix Orthopaedics.
Over the past six months, the Zacks Rank #1 (Strong Buy) stock has gained 8.9% against the industry's decline of 2.5%. The current level also compares favorably with the S&P 500 index’s 2.8% decline.
What’s Working in Favor of Smith & Nephew?
Strong franchise performance:
Of late, the company is showing strong revenue performance across majority of its key operating franchises. In the last reported quarter, growth within the company’s Reconstruction segment was driven by strong momentum within the knees and hips sub-segments. The knees sub-segment was driven by double-digit growth in JOURNEY II, ANTHEM and the LEGION Revision System. Growth within the hips subsegment came from the company’s increased focus on POLAR3 and REDAPT Revision System. The launch of the dual mobility product with its OXINIUM bearing has been a key development within this sub-segment.
Within the Arthroscopic Enabling Technologies segment, one crucial development has been the launch of the Flow 90 Wand, which expanded the application of the company’s COBLATION technology. The company is also witnessing a sharp increase in NAVIO robot and capital sales within its Surgical Business segment.
The franchise of Sports Medicine and Trauma also reported solid growth in the last quarter. This segment was driven by growth of the company’s joint repair business, especially doubled sales of its REGENETEN rotator cuff repair device. The franchise of Trauma and Extremities reported growth on the company’s EVOS and INTERTAIN product lines. The Advanced Wound Management segment also registered single-digit growth buoyed by strong sales at its Advanced Wound Care and Advanced Wound Devices portfolios.
Strategic acquisitions:
In January, the company acquired Ceterix Orthopaedics, which strengthened its sports medicine portfolio. The market is currently upbeat about Smith & Nephew’s plan to take over Brainlab Orthopaedic Joint Reconstruction Business to augment its newly-launchedmulti-asset digital surgery and robotic ecosystem. The company has also announced an agreement to acquire Osiris Therapeutics which should enable Smith & Nephew to gain a strong foothold in the market of high growth regenerative medicine.
Strong geographic performance:
In the fourth quarter of 2018, the company reported revenue growth of 3% in the United States and 8% across the emerging markets. Revenue growth from China was in double digits. Despite a decline in revenues from its U.K market, the newly-appointed management in Germany is expected to result in solid growth recovery.
Which Way are Estimates Treading?
Further, Smith & Nephew’s estimate revision trend for the current year is favorable. In the past 60 days, two estimates moved up while none shifted down. Consequently, estimates were up from $2 per share to $2.02.
Zacks Rank and Other Key Picks
Currently, Smith & Nephew sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Penumbra, Inc. (PEN - Free Report) and Varian Medical Systems, Inc . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker’s long-term earnings growth rate is projected at 10%
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Varian’s long-term earnings growth rate is projected at 8%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>